Evidence map›Paper›PMID 25238615›Full record

ArticlePloS one2014

A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND.

Dov Shiffman, Guillaume Pare, Rainer Oberbauer, Judy Z Louie, Charles M Rowland, James J Devlin, Johannes F Mann, Matthew J McQueen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Implications of Sphingolipid Metabolites in Kidney Diseases.International journal of molecular sciences · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Ceramides in Metabolism: Key Lipotoxic Players.Annual review of physiology · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Dov ShiffmanCelera, Alameda, CA, United States of America.
Guillaume ParePopulation Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
Rainer OberbauerDepartment of Nephrology, KH Elisabethinen, Linz, Austria and Department of Nephrology, Medical University of Vienna, Vienna, Austria.
Judy Z LouieCelera, Alameda, CA, United States of America.
Charles M RowlandCelera, Alameda, CA, United States of America.
James J DevlinCelera, Alameda, CA, United States of America.
Johannes F MannDepartment of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Germany.
Matthew J McQueenPopulation Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
McMaster University · CAFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKrankenhaus der Elisabethinen · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although albuminuria and subsequent advanced stage chronic kidney disease are common among patients with diabetes, the rate of increase in albuminuria varies among patients. Since genetic variants associated with estimated glomerular filtration rate (eGFR) were identified in cross sectional studies, we asked whether these variants were also associated with rate of increase in albuminuria among patients with diabetes from ONTARGET and TRANSCEND-randomized controlled trials of ramipril, telmisartan, both, or placebo. For 16 genetic variants associated with eGFR at a genome-wide level, we evaluated the association with annual rate of increase in albuminuria estimated from urine albumin:creatinine ratio (uACR). One of the variants (rs267734) was associated with rate of increase in albuminuria. The annual rate of increase in albuminuria among risk homozygotes (69% of the study population) was 11.3% (95%CI; 7.5% to 15.3%), compared with 5.0% (95%CI; 3.3% to 6.8%) for heterozygotes (27% of the population), and 1.7% (95%CI; -1.7% to 5.3%) for non-risk homozygotes (4% of the population); P = 0.0015 for the difference between annual rates in the three genotype groups. These estimates were adjusted for age, sex, ethnicity, and principal component of genetic heterogeneity. Among patients without albuminuria at baseline (uACR<30 mg/g), each risk allele was associated with 50% increased risk of incident albuminuria (OR = 1.50; 95%CI 1.15 to 1.95; P = 0.003) after further adjustment for traditional risk factors including baseline uACR and eGFR. The rs267734 variant is in almost perfect linkage-disequilibrium (r2 = 0.94) with rs267738, a single nucleotide polymorphism encoding a glutamic acid to alanine change at position 115 of the ceramide synthase 2 (CERS2) encoded protein. However, it is unknown whether CERS2 function influences albuminuria. In conclusion, we found that rs267734 in CERS2 is associated with rate of increase in albuminuria among patients with diabetes and elevated risk of cardiovascular disease.

Indexed as

Polymorphism, Single NucleotideAgedAlbuminuriaDiabetes MellitusDiabetic NephropathiesFemaleGlomerular Filtration RateHumansLinkage DisequilibriumMaleMembrane ProteinsMiddle AgedPrincipal Component AnalysisRandomized Controlled Trials as TopicSphingosine N-AcyltransferaseTumor Suppressor ProteinsCERS2 protein, humanMembrane ProteinsSphingosine N-AcyltransferaseTumor Suppressor Proteins

Identifiers

PMID25238615
PMCPMC4169514
OpenAlexW1996486490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.